Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin : A retrospective analysis of 1061 cases in Marseille, France
Copyright © 2020 Elsevier Ltd. All rights reserved..
BACKGROUND: In France, the combination hydroxychloroquine (HCQ) and azithromycin (AZ) is used in the treatment of COVID-19.
METHODS: We retrospectively report on 1061 SARS-CoV-2 positive tested patients treated for at least three days with the following regimen: HCQ (200 mg three times daily for ten days) + AZ (500 mg on day 1 followed by 250 mg daily for the next four days). Outcomes were death, clinical worsening (transfer to ICU, and >10 day hospitalization) and viral shedding persistence (>10 days).
RESULTS: A total of 1061 patients were included in this analysis (46.4% male, mean age 43.6 years - range 14-95 years). Good clinical outcome and virological cure were obtained in 973 patients within 10 days (91.7%). Prolonged viral carriage was observed in 47 patients (4.4%) and was associated to a higher viral load at diagnosis (p < .001) but viral culture was negative at day 10. All but one, were PCR-cleared at day 15. A poor clinical outcome (PClinO) was observed for 46 patients (4.3%) and 8 died (0.75%) (74-95 years old). All deaths resulted from respiratory failure and not from cardiac toxicity. Five patients are still hospitalized (98.7% of patients cured so far). PClinO was associated with older age (OR 1.11), severity of illness at admission (OR 10.05) and low HCQ serum concentration. PClinO was independently associated with the use of selective beta-blocking agents and angiotensin II receptor blockers (p < .05). A total of 2.3% of patients reported mild adverse events (gastrointestinal or skin symptoms, headache, insomnia and transient blurred vision).
CONCLUSION: Administration of the HCQ+AZ combination before COVID-19 complications occur is safe and associated with a very low fatality rate in patients.
| Errataetall: |
CommentIn: Intern Emerg Med. 2020 Aug;15(5):841-843. - PMID 32474851 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Travel medicine and infectious disease - 35(2020) vom: 01. Mai, Seite 101738 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
4QWG6N8QKH |
|---|
| Anmerkungen: |
Date Completed 10.07.2020 Date Revised 13.11.2023 published: Print-Electronic CommentIn: Intern Emerg Med. 2020 Aug;15(5):841-843. - PMID 32474851 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.tmaid.2020.101738 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309706203 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309706203 | ||
| 003 | DE-627 | ||
| 005 | 20231225134515.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.tmaid.2020.101738 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1032.xml |
| 035 | |a (DE-627)NLM309706203 | ||
| 035 | |a (NLM)32387409 | ||
| 035 | |a (PII)S1477-8939(20)30217-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Million, Matthieu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin |b A retrospective analysis of 1061 cases in Marseille, France |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.07.2020 | ||
| 500 | |a Date Revised 13.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Intern Emerg Med. 2020 Aug;15(5):841-843. - PMID 32474851 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: In France, the combination hydroxychloroquine (HCQ) and azithromycin (AZ) is used in the treatment of COVID-19 | ||
| 520 | |a METHODS: We retrospectively report on 1061 SARS-CoV-2 positive tested patients treated for at least three days with the following regimen: HCQ (200 mg three times daily for ten days) + AZ (500 mg on day 1 followed by 250 mg daily for the next four days). Outcomes were death, clinical worsening (transfer to ICU, and >10 day hospitalization) and viral shedding persistence (>10 days) | ||
| 520 | |a RESULTS: A total of 1061 patients were included in this analysis (46.4% male, mean age 43.6 years - range 14-95 years). Good clinical outcome and virological cure were obtained in 973 patients within 10 days (91.7%). Prolonged viral carriage was observed in 47 patients (4.4%) and was associated to a higher viral load at diagnosis (p < .001) but viral culture was negative at day 10. All but one, were PCR-cleared at day 15. A poor clinical outcome (PClinO) was observed for 46 patients (4.3%) and 8 died (0.75%) (74-95 years old). All deaths resulted from respiratory failure and not from cardiac toxicity. Five patients are still hospitalized (98.7% of patients cured so far). PClinO was associated with older age (OR 1.11), severity of illness at admission (OR 10.05) and low HCQ serum concentration. PClinO was independently associated with the use of selective beta-blocking agents and angiotensin II receptor blockers (p < .05). A total of 2.3% of patients reported mild adverse events (gastrointestinal or skin symptoms, headache, insomnia and transient blurred vision) | ||
| 520 | |a CONCLUSION: Administration of the HCQ+AZ combination before COVID-19 complications occur is safe and associated with a very low fatality rate in patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Azithromycin | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Hydroxychloroquine | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 650 | 7 | |a Azithromycin |2 NLM | |
| 650 | 7 | |a 83905-01-5 |2 NLM | |
| 700 | 1 | |a Lagier, Jean-Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Gautret, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Colson, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Fournier, Pierre-Edouard |e verfasserin |4 aut | |
| 700 | 1 | |a Amrane, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Hocquart, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Mailhe, Morgane |e verfasserin |4 aut | |
| 700 | 1 | |a Esteves-Vieira, Vera |e verfasserin |4 aut | |
| 700 | 1 | |a Doudier, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Aubry, Camille |e verfasserin |4 aut | |
| 700 | 1 | |a Correard, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Giraud-Gatineau, Audrey |e verfasserin |4 aut | |
| 700 | 1 | |a Roussel, Yanis |e verfasserin |4 aut | |
| 700 | 1 | |a Berenger, Cyril |e verfasserin |4 aut | |
| 700 | 1 | |a Cassir, Nadim |e verfasserin |4 aut | |
| 700 | 1 | |a Seng, Piseth |e verfasserin |4 aut | |
| 700 | 1 | |a Zandotti, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Dhiver, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Ravaux, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Tomei, Christelle |e verfasserin |4 aut | |
| 700 | 1 | |a Eldin, Carole |e verfasserin |4 aut | |
| 700 | 1 | |a Tissot-Dupont, Hervé |e verfasserin |4 aut | |
| 700 | 1 | |a Honoré, Stéphane |e verfasserin |4 aut | |
| 700 | 1 | |a Stein, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Jacquier, Alexis |e verfasserin |4 aut | |
| 700 | 1 | |a Deharo, Jean-Claude |e verfasserin |4 aut | |
| 700 | 1 | |a Chabrière, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Levasseur, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Fenollar, Florence |e verfasserin |4 aut | |
| 700 | 1 | |a Rolain, Jean-Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Obadia, Yolande |e verfasserin |4 aut | |
| 700 | 1 | |a Brouqui, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Drancourt, Michel |e verfasserin |4 aut | |
| 700 | 1 | |a La Scola, Bernard |e verfasserin |4 aut | |
| 700 | 1 | |a Parola, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Raoult, Didier |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Travel medicine and infectious disease |d 2003 |g 35(2020) vom: 01. Mai, Seite 101738 |w (DE-627)NLM16457655X |x 1873-0442 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2020 |g day:01 |g month:05 |g pages:101738 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.tmaid.2020.101738 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2020 |b 01 |c 05 |h 101738 | ||